Prescription drug · ANDA
rifampin NDC 50090-5709
Rifampin 300 mg/1 · Capsule · Oral · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-5709-0 | 50090570900 | 30 CAPSULE in 1 BOTTLE (50090-5709-0)Marketed from Sep 24, 2021 | |
| 50090-5709-3 | 50090570903 | 60 CAPSULE in 1 BOTTLE (50090-5709-3)Marketed from Sep 24, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- rifampin
- Generic name (nonproprietary)
- rifampin
- Active ingredients
- Rifampin — 300 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- A-S Medication Solutions
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 090034
- Marketing start
- Listing expires
- Other FDA classes
- Rifamycins (Chemical structure)
- Identifiers
- Product ID 50090-5709_37783510-9524-4bee-89d1-c96e36d6791aSPL ID 37783510-9524-4bee-89d1-c96e36d6791aSPL set ID d53b6998-6e3b-4c6f-8465-2af6897d1efeRxCUI 198202UNII VJT6J7R4TR
- Pharmacologic class
- Rifamycin Antibacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450090570900followed by a unit qualifier and the quantityPackage 50090-5709-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regim…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 090034
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| rifampin | Rifampin 300 mg/1 | CapsuleOral | Bryant Ranch Prepack | 71335-2613 |
| rifampin | Rifampin 150 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-658 |
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | American Health Packaging | 60687-575 |
| rifampin | Rifampin 300 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-659 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | American Health Packaging | 60687-586 |
| rifampin | Rifampin 300 mg/1 | CapsuleOral | Major Pharmaceuticals | 0904-7315 |